Alphamab Oncology (FRA:3NK) Institutional Ownership: 3.59% (As of Aug. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:3NK Alphamab Oncology FRA:3NK
55 GF Score
Price €0.88
GF Value €0.82
! 4 Warning Signs
View Full Analysis

What is Alphamab Oncology Institutional Ownership?

Alphamab Oncology FRA:3NK +0.57% 55 Institutional Ownership is 3.59% as of Aug. 20, 2026. GuruFocus rates FRA:3NK with a GF Score™ of 55/100 and a GF Value™ of €0.82. The stock has 4 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Alphamab Oncology's institutional ownership is 3.59%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Alphamab Oncology's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Alphamab Oncology's Float Percentage Of Total Shares Outstanding is 0.00%.

Alphamab Oncology Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Alphamab Oncology's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alphamab Oncology Institutional Ownership Chart

Alphamab Oncology Historical Data

The historical data trend for Alphamab Oncology can be seen below:

2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30 2026-07-31
Institutional Ownership 2.90 2.92 3.29 3.37 3.66 3.51 3.40 3.52 3.55 3.59
FRA:3NK
55GF Score
Alphamab Oncology FRA:3NK
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alphamab Oncology Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 3.59% mean?
Alphamab Oncology (FRA:3NK) has a Institutional Ownership of 3.59% as of Aug. 20, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Alphamab Oncology and its competitors.
Is Alphamab Oncology's Institutional Ownership too high?
Alphamab Oncology's current Institutional Ownership is 3.59%. Overall, Alphamab Oncology has a GF Score™ of 55/100, reflecting its overall financial health beyond just this single metric.
How does Alphamab Oncology's Institutional Ownership compare to VRTX and REGN?
Alphamab Oncology's Institutional Ownership of 3.59% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Alphamab Oncology and its competitors. Alphamab Oncology's current Institutional Ownership is 3.59%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alphamab Oncology stock overvalued right now?
Alphamab Oncology (FRA:3NK) has a current Institutional Ownership of 3.59%. The stock's GF Value™ is €0.82, compared to a current price of €0.88 — trading 7.3% above its estimated fair value. The current Institutional Ownership is 3.59%. Alphamab Oncology's overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Alphamab Oncology (FRA:3NK), the current Institutional Ownership is 3.59% as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Alphamab Oncology (FRA:3NK) Overvalued in 2026?

Based on GuruFocus' analysis, Alphamab Oncology stock appears to be overvalued. The current stock price of €0.88 is trading 7.3% above its estimated GF Value™ of €0.82.

Key valuation signals for FRA:3NK:

  • Institutional Ownership: 3.59%
  • GF Value™: €0.82 vs. price of €0.88 (7.3% above fair value)
  • GF Score™: 55/100 with 4 warning signs

No single metric tells the full story. See the FRA:3NK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Alphamab Oncology Business Description

Other Exchanges 09966:Hong Kong3NK:Germany
Address No. 175 Fangzhou Road, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN, 215127
Alphamab Oncology is a biopharmaceutical company in China with a fully integrated proprietary technology platform in ADCs, bispecific antibodies, and multifunctional protein engineering. The Company is principally engaged in the research and development, manufacturing, and commercialisation of biologics of oncology. It delivers therapeutic biologics by applying its drug discovery and development capabilities. Its product portfolio includes Envafolimab (KN035), KN026, JSKN003, JSKN016, JSKN033, JSKN022, JSKN027, JSKN021, KN019, and KN046.
55GF Score

Get the complete analysis for FRA:3NK

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.88
Price
€0.82
GF Value